ConductScience.org, home

Paper326003

Passive immunotherapy of cancer in animals and man.

Rosenberg SA and 1 other. Adv Cancer Res, 1977. Cited by 130 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Passive immunotherapy of cancer in animals and man. Papers, record 326003. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/326003

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Passive immunotherapy of cancer in animals and man.
PubMed
Journal
Adv Cancer Res
PubMed
Year
1977
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
130
iCite
Relative citation ratio, by iCite
2.42
iCite
Revised in PubMed
2019-10-28
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rosenberg SAS A
2Terry WDW D

Source PubMed

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunization, PassiveMajor topic
NeoplasmsMajor topic
Animals
Antibodies
Antibodies, Heterophile
Antineoplastic Agents
Binding, Competitive
Bone Marrow
Bone Marrow Cells
Bone Marrow Transplantation
Humans
Immunotherapy
In Vitro Techniques
Isoantibodies
Lymphocyte Transfusion
Lymphocytes
Neoplasms, Experimental
RNA
Subcellular Fractions
Transfer Factor
Transplantation, Homologous

Source PubMed

Cited by58

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 130 citations.

PMIDTitleJournalYearIn PapersSource
42,482,408Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions.Cancer2026https://conductscience.org/library/papers/42482408PubMed
40,900,811Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy.MedComm (2020)2025https://conductscience.org/library/papers/40900811PubMed
38,085,594Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors.JCI Insight2024https://conductscience.org/library/papers/38085594PubMed
36,941,828A Review of CAR-T Therapy in Pediatric and Young Adult B-Lineage Acute Leukemia: Clinical Perspectives in Singapore.Onco Targets Ther2023https://conductscience.org/library/papers/36941828PubMed
34,386,077Cancer immunotherapy: A comprehensive appraisal of its modes of application.Oncol Lett2021https://conductscience.org/library/papers/34386077PubMed
33,824,633Smarter cures to combat COVID-19 and future pathogens: a review.Environ Chem Lett2021https://conductscience.org/library/papers/33824633PubMed
32,432,843T Cell Receptor Engineered Lymphocytes for Cancer Therapy.Curr Protoc Immunol2020https://conductscience.org/library/papers/32432843PubMed
32,418,986Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication.Cancer Gene Ther2020https://conductscience.org/library/papers/32418986PubMed
30,555,581Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?Theranostics2018https://conductscience.org/library/papers/30555581PubMed
30,194,234Radioactive (90Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer.Proc Natl Acad Sci U S A2018https://conductscience.org/library/papers/30194234PubMed
29,396,610Arsenic trioxide: insights into its evolution to an anticancer agent.J Biol Inorg Chem2018https://conductscience.org/library/papers/29396610PubMed
28,845,462Potential Cancer Prevention and Treatment by Silencing the Killer Cell Immunoglobulin-like Receptor Gene in Natural Killer Cells Derived from Induced Pluripotent Stem Cells.Enliven J Stem Cell Res Regen Med2016https://conductscience.org/library/papers/28845462PubMed
27,372,731Chimeric antigen receptors: driving immunology towards synthetic biology.Curr Opin Immunol2016https://conductscience.org/library/papers/27372731PubMed
27,081,677Antibody Therapeutics in Oncology.Immunotherapy (Los Angel)2016https://conductscience.org/library/papers/27081677PubMed
24,907,378IL-2: the first effective immunotherapy for human cancer.J Immunol2014https://conductscience.org/library/papers/24907378PubMed
24,274,181Chimeric antigen receptor therapy for cancer.Annu Rev Med2014https://conductscience.org/library/papers/24274181PubMed
22,437,939Adoptive immunotherapy for cancer: harnessing the T cell response.Nat Rev Immunol2012https://conductscience.org/library/papers/22437939PubMed
19,473,517Progress and challenges in the vaccine-based treatment of head and neck cancers.J Exp Clin Cancer Res2009https://conductscience.org/library/papers/19473517PubMed
17,476,350Principles of adoptive T cell cancer therapy.J Clin Invest2007https://conductscience.org/library/papers/17476350PubMed
8,699,241Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.J Neurooncol1996https://conductscience.org/library/papers/8699241PubMed

See all 58 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/326003

GET https://conductscience.org/api/papers/v1/326003/cited_by?page=2